150 related articles for article (PubMed ID: 7685953)
1. Use of prostaglandin E1 in crossmatch-negative liver transplant recipients treated with FK 506.
Takaya S; Bronsther O; Abu-Elmagd K; Ramos H; Fung JJ; Todo S; Starzl TE
Transplant Proc; 1993 Jun; 25(3):2381-5. PubMed ID: 7685953
[No Abstract] [Full Text] [Related]
2. FK 506 treatment of intractable rejection after liver transplantation.
Jost U; Winkler M; Ringe B; Rodeck B; Pichlmayr R
Transplant Proc; 1993 Aug; 25(4):2686-7. PubMed ID: 7689276
[No Abstract] [Full Text] [Related]
3. Tacrolimus (FK 506) for rescue of chronic rejection following orthotopic liver transplantation.
Sher LS; Cosenza CA; Petrovic LM; Rojter S; Hoffman A; Lopez RR; Meehan M; Pan SH; Vierling J; Makowka L
Transplant Proc; 1996 Apr; 28(2):1011-3. PubMed ID: 8623212
[No Abstract] [Full Text] [Related]
4. FK 506 as treatment of late acute rejection in liver transplant patients.
Rucay P; Samuel D; Farges O; Reynes M; Bismuth H
Transplant Proc; 1995 Feb; 27(1):1105-6. PubMed ID: 7533354
[No Abstract] [Full Text] [Related]
5. Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group.
Klintmalm GB; Goldstein R; Gonwa T; Wiesner RH; Krom RA; Shaw BW; Stratta R; Ascher NL; Roberts JW; Lake J
Transplant Proc; 1993 Feb; 25(1 Pt 1):679-88. PubMed ID: 7679840
[TBL] [Abstract][Full Text] [Related]
6. Significance of a T-lymphocytotoxic crossmatch in liver and combined liver-kidney transplantation.
Neumann UP; Lang M; Moldenhauer A; Langrehr JM; Glanemann M; Kahl A; Frei U; Bechstein WO; Neuhaus P
Transplantation; 2001 Apr; 71(8):1163-8. PubMed ID: 11374419
[TBL] [Abstract][Full Text] [Related]
7. Low incidence of chronic rejection in patients experiencing histological acute rejection without simultaneous impairment in liver function tests.
Farges O; Nocci Kalil A; Sebagh M; Reynes M; Bismuth H
Transplant Proc; 1995 Feb; 27(1):1142-3. PubMed ID: 7878827
[No Abstract] [Full Text] [Related]
8. Experience in one center of combined kidney and liver transplantation in 22 patients: incidence of graft rejection and long-term graft outcome.
Larue JR; Hiesse C; Samuel D; Blanchet P; Bensadoun H; Benoit G; Castaing D; Adam R; Charpentier B; Bismuth H
Transplant Proc; 1997; 29(1-2):243-4. PubMed ID: 9122981
[No Abstract] [Full Text] [Related]
9. Impact of immunosuppression in liver transplantation across a positive crossmatch.
Lang M; Neumann U; Knoop M; Bechstein WO; Neuhaus P
Transplant Proc; 1998 Jun; 30(4):1466-7. PubMed ID: 9636595
[No Abstract] [Full Text] [Related]
10. FK 506 rescue therapy: the rapidity of rejection reversal is related to the subsequent development of CMV disease.
Woodle ES; Perdrizet GA; So S; Jendrisak MD; White HM; Marsh JW
Transplant Proc; 1993 Apr; 25(2):1992-3. PubMed ID: 7682360
[No Abstract] [Full Text] [Related]
11. Tolerance induction by liver grafting and FK 506 treatment in nonhuman primates.
Gotoh M; Monden M; Kanai T; Umeshita K; Wang K; Ukei T; Dono K; Tono T; Murata M; Tanimoto J
Transplant Proc; 1991 Dec; 23(6):3265-8. PubMed ID: 1721431
[No Abstract] [Full Text] [Related]
12. Early steroid-resistant rejection following orthotopic liver transplantation: new aspects of treatment with FK 506 instead of OKT3?
Dé P; Bechstein WO; Blumhardt G; Lange D; Schattenfroh N; Neuhaus P
Transplant Proc; 1993 Aug; 25(4):2693-4. PubMed ID: 7689279
[No Abstract] [Full Text] [Related]
13. Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy.
Takaya S; Duquesnoy R; Iwaki Y; Demetris J; Yagihashi A; Bronsther O; Iwatsuki S; Starzl TE
Transplant Proc; 1991 Feb; 23(1 Pt 1):396-9. PubMed ID: 1703691
[No Abstract] [Full Text] [Related]
14. FK 506 rescue therapy in liver transplantation: outcome and complications.
McDiarmid SV; Klintmalm G; Busuttil RW
Transplant Proc; 1991 Dec; 23(6):2996-9. PubMed ID: 1721339
[No Abstract] [Full Text] [Related]
15. Reduction of primary nonfunction with prostaglandin E1 after clinical liver transplantation.
Takaya S; Doyle H; Todo S; Irish W; Fung JJ; Starzl TE
Transplant Proc; 1995 Apr; 27(2):1862-7. PubMed ID: 7725533
[No Abstract] [Full Text] [Related]
16. FK 506 used as rescue therapy for refractory liver allograft rejection.
Chen CL; Eng HL; Chen YS; Kuo YC; Sun CK
Transplant Proc; 1994 Aug; 26(4):1927-9. PubMed ID: 7520612
[No Abstract] [Full Text] [Related]
17. Early cellular rejection treated with high-dose intravenous corticosteroid therapy is associated with a decrease in the incidence of steroid-resistant rejection and graft failure from rejection.
Wiesner RH; Porayko MK; Wahlstrom HE; Gores GJ; Kamath PS; Hay JE; Krom RA
Transplant Proc; 1993 Apr; 25(2):1791-3. PubMed ID: 7682352
[No Abstract] [Full Text] [Related]
18. Incidence and patterns of rejection using different induction therapies in liver transplant recipients.
Elkashab M; Reizig M; Greig PD; Cameron R; Phillips MJ; Chung S; Cattral M; Levy G
Transplant Proc; 1994 Oct; 26(5):2669-71. PubMed ID: 7940835
[No Abstract] [Full Text] [Related]
19. Living-donor liver transplantation at the University of Tokyo, 1996-2011: the impact of HLA matching and a positive crossmatch on long-term survival and tolerance.
Waki K; Sugawara Y; Mizuta K; Fujita H; Kadowaki T; Kokudo N
Clin Transpl; 2011; ():223-35. PubMed ID: 22755416
[TBL] [Abstract][Full Text] [Related]
20. Strategy of FK 506 therapy in liver transplant patients: effect of graft function.
Abu-Elmagd KM; Fung JJ; Alessiani M; Jain A; Takaya S; Venkataramanan R; Warty VS; Shannon W; Todo S; Tzakis A
Transplant Proc; 1991 Dec; 23(6):2771-4. PubMed ID: 1721272
[No Abstract] [Full Text] [Related]
[Next] [New Search]
